Ravulizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder.
Pittock SJ, Barnett M, Bennett JL, Berthele A, de Sèze J, Levy M, Nakashima I, Oreja-Guevara C, Palace J, Paul F, Pozzilli C, Yountz M, Allen K, Mashhoon Y, Kim HJ.
Ann Neurol. 2023 Jun;93(6):1053-1068. doi: 10.1002/ana.26626. Epub 2023 Apr 5.
A case of anti-aquaporin-4 antibody-positive optic neuritis treated by selective immunoadsorption.
Naganuma T, Furusawa Y, Hanaoka A, Takemoto Y, Uchida J.
Transfus Apher Sci. 2021 Feb;60(1):102969. doi: 10.1016/j.transci.2020.102969. Epub 2020 Oct 20.
Role of C5 inhibitors in neuromyelitis optica spectrum disorders with seropositive anti-aquaporin-4 antibody: A systematic review and meta-analysis.
Makkawi S, Salamatullah HK, Alkhiri A, Faidah DE, Afif LM, Bukhari JI, Abulaban A, Al Malik Y, Levy M.
Mult Scler Relat Disord. 2024 May;85:105524. doi: 10.1016/j.msard.2024.105524. Epub 2024 Mar 1.
Myelin oligodendrocyte glycoprotein antibodies in neurological disease.
Reindl M, Waters P.
Nat Rev Neurol. 2019 Feb;15(2):89-102. doi: 10.1038/s41582-018-0112-x.
Anti-aquaporin 4 antibody-positive acute disseminated encephalomyelitis.
Okumura A, Nakazawa M, Igarashi A, Abe S, Ikeno M, Nakahara E, Yamashiro Y, Shimizu T, Takahashi T.
Brain Dev. 2015 Mar;37(3):339-43. doi: 10.1016/j.braindev.2014.04.013. Epub 2014 May 16.
Impact of comorbid Sjogren syndrome in anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorders.
Akaishi T, Takahashi T, Fujihara K, Misu T, Fujimori J, Takai Y, Nishiyama S, Abe M, Ishii T, Aoki M, Nakashima I.
J Neurol. 2021 May;268(5):1938-1944. doi: 10.1007/s00415-020-10377-6. Epub 2021 Jan 8.
MRI characteristics of neuromyelitis optica spectrum disorder: an international update.
Kim HJ, Paul F, Lana-Peixoto MA, Tenembaum S, Asgari N, Palace J, Klawiter EC, Sato DK, de Seze J, Wuerfel J, Banwell BL, Villoslada P, Saiz A, Fujihara K, Kim SH; Guthy-Jackson Charitable Foundation NMO International Clinical Consortium & Biorepository.
Neurology. 2015 Mar 17;84(11):1165-73. doi: 10.1212/WNL.0000000000001367. Epub 2015 Feb 18.
Affinity-matured 'aquaporumab' anti-aquaporin-4 antibody for therapy of seropositive neuromyelitis optica spectrum disorders.
Duan T, Tradtrantip L, Phuan PW, Bennett JL, Verkman AS.
Neuropharmacology. 2020 Jan 1;162:107827. doi: 10.1016/j.neuropharm.2019.107827. Epub 2019 Oct 22.
Anti-aquaporin-4 antibody-positive dorsal midbrain syndrome.
Lee J, Jeong SH, Park SM, Sohn EH, Lee AY, Kim JM, Jo HJ, Lee YH, Kim JS.
Mult Scler. 2015 Apr;21(4):477-80. doi: 10.1177/1352458514541977. Epub 2014 Jul 10.
Neuromyelitis Optica Spectrum Disorder With Anti-Aquaporin-4 Antibody: Outcome Prediction Models.
Wang L, Du L, Li Q, Li F, Wang B, Zhao Y, Meng Q, Li W, Pan J, Xia J, Wu S, Yang J, Li H, Ma J, ZhangBao J, Huang W, Chang X, Tan H, Yu J, Zhou L, Lu C, Wang M, Dong Q, Lu J, Zhao C, Quan C.
Front Immunol. 2022 Mar 31;13:873576. doi: 10.3389/fimmu.2022.873576. eCollection 2022.
